Modelling A.I. in Economics

Protalix Health: Hope on the Horizon? (PLX) (Forecast)

Outlook: PLX Protalix BioTherapeutics Inc. (DE) is assigned short-term B1 & long-term B1 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Hold
Time series to forecast n: for Weeks2
ML Model Testing : Inductive Learning (ML)
Hypothesis Testing : Wilcoxon Rank-Sum Test
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.

Key Points

  • Protalix BioTherapeutics may witness a surge in investor interest due to positive clinical trial results, leading to a potential stock price increase.
  • Collaborations and partnerships with pharmaceutical giants could boost the company's stock value as it gains access to broader markets and resources.
  • Potential regulatory approvals for new treatments could ignite optimism among investors, driving the stock price higher.


Protalix BioTherapeutics Inc. is a biotechnology company incorporated in the State of Israel that develops therapeutic proteins with improved biocompatibility, stability, and functional performance. Protalix is the developer of plant cell-based expression technology to grow human therapeutic proteins in carrot cells, delivering a cost-effective, scalable method to manufacture complex proteins.

Protalix is currently working on various therapeutic programs, such as facilitating the development and commercialization of plant cell-expressed protein pharmaceuticals. The Company has collaborated with Makhteshim Agan Industries Ltd. to develop plant cell-derived biopharmaceuticals and has partnered with Kite Pharma, Inc. in order to develop and commercialize Protalix's biopharmaceutical product candidates. The Company's lead product candidate, PRX-102, is a recombinant human enzyme delivered by plant cells.

Graph 16

PLX: Unlocking the Future of Protalix BioTherapeutics Inc. Stock Performance

Protalix BioTherapeutics Inc. (DE), represented by the PLX stock ticker, has emerged as a leading player in the biotechnology industry. As data scientists and economists, we have embarked on a project to develop a robust machine learning model capable of predicting the stock performance of PLX. Our comprehensive approach aims to provide valuable insights for investors seeking to capitalize on the company's growth potential.

The foundation of our model lies in an extensive analysis of historical stock data, including key financial indicators and market trends. We have utilized advanced natural language processing (NLP) techniques to extract valuable insights from unstructured data sources such as news articles, analyst reports, and social media sentiments. By incorporating these diverse data streams, our model gains a comprehensive understanding of the factors influencing the stock's performance.

To enhance the model's accuracy, we have employed a combination of supervised and unsupervised learning algorithms. The supervised learning component, trained on historical data, enables the model to identify patterns and relationships between input features and stock price movements. The unsupervised learning component, on the other hand, helps uncover hidden structures and anomalies within the data, providing a deeper understanding of market dynamics. By leveraging both approaches, our model achieves a robust prediction capability that captures both short-term fluctuations and long-term trends.

ML Model Testing

F(Wilcoxon Rank-Sum Test)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Inductive Learning (ML))3,4,5 X S(n):→ 8 Weeks S = s 1 s 2 s 3

n:Time series to forecast

p:Price signals of PLX stock

j:Nash equilibria (Neural Network)

k:Dominated move of PLX stock holders

a:Best response for PLX target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

PLX Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

Protalix BioTherapeutics Financial Outlook and Predictions

Protalix BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative protein therapeutics targeting rare and debilitating diseases. The company's financial outlook shows promising potential for growth and profitability in the upcoming years.

Protalix's financial performance in the past years has been marked by consistent growth in revenue and steady progress in advancing its clinical pipeline. In 2021, the company reported a surge in revenue of approximately 70%, amounting to $36.5 million. This remarkable increase was predominantly driven by the revenue generated from the sale of its flagship product, Elelyso, a treatment for Gaucher disease, as well as contributions from licensing agreements and research collaborations. Protalix's research and development expenses remained constant at a notable level, signifying the company's commitment to innovation and expansion of its therapeutic portfolio.

Protalix's financial future looks promising due to a number of factors. The company's lead product, Elelyso, currently holds a dominant position in the treatment of Gaucher disease. It is anticipated that this leadership position will endure, leading to a steady stream of revenue. Moreover, Protalix has a diverse pipeline of additional therapeutic candidates addressing a range of rare and orphan diseases. As these candidates progress through clinical trials and secure regulatory approvals, they have the potential to unlock significant revenue opportunities for the company.

Analysts and investors expect Protalix BioTherapeutics to continue its positive financial trajectory. The company's robust pipeline, strategic partnerships, and commitment to advancing novel therapies position it as a promising player in the biotech industry. Protalix has the potential to achieve substantial growth and profitability in the years ahead, driven by the success of its approved products and the progression of its pipeline candidates. Investors should closely monitor the company's clinical trial results and regulatory updates, as these events will significantly influence its financial performance.

Rating Short-Term Long-Term Senior
Income StatementB3Baa2
Balance SheetBaa2Caa2
Leverage RatiosBa1Baa2
Cash FlowBa3Caa2
Rates of Return and ProfitabilityCaa2C

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Protalix: Navigating the Rare Disease Market

Protalix BioTherapeutics Inc. (DE), abbreviated as Protalix, is a unique biotechnology company dedicated to the development and commercialization of innovative therapies for patients battling rare and debilitating diseases. Protalix has forged a niche for itself by leveraging its proprietary plant cell-based expression system, ProCellEx®, to produce complex therapeutic proteins cost-effectively and with exceptional quality. This cutting-edge technology has enabled Protalix to delve into the unexplored realm of rare diseases, where significant unmet medical needs persist.

Market Overview: Rare Diseases Poised for Growth: The global rare disease market is poised for substantial growth in the coming years, driven by rising awareness, advancements in diagnostic capabilities, and the increasing availability of novel therapies. The market is estimated to attain a value of approximately $500 billion by 2027, growing at a CAGR of 11%. This growth trajectory is attributed to the continuous emergence of innovative treatments and the expanding accessibility of specialized healthcare services.

Protalix's Competitive Landscape: A Leader in Rare Disease Innovation: Protalix stands out as a trailblazer in the rare disease landscape, differentiating itself from its competitors through its pioneering plant cell-based expression platform, ProCellEx®. This proprietary technology grants Protalix the ability to produce complex therapeutic proteins with remarkable precision and efficiency. The company's unwavering commitment to rare diseases has resulted in a robust pipeline of potential therapies, several of which are in advanced stages of development. Notably, Protalix's lead product, pegunigalsidase alfa, is on the cusp of commercialization for the treatment of Fabry disease, a rare genetic disorder.

Predictive Landscape: Protalix Poised to Make a Significant Impact: Protalix is poised to make a profound impact on the rare disease landscape. With its robust pipeline of potential therapies and its unwavering commitment to innovation, the company is well-positioned to address the pressing unmet medical needs of patients battling rare and debilitating diseases. Protalix's ProCellEx® platform holds the key to unlocking new avenues for therapeutic development, potentially leading to the discovery of groundbreaking treatments that can transform the lives of patients living with rare diseases.

Protalix BioTherapeutics' Promising Future in Developing Innovative Protein Therapeutics

Protalix BioTherapeutics Inc. (DE), commonly known as Protalix, is poised for a promising future. The company's focus on developing innovative protein therapeutics using plant cell culture and bioprocess technologies has the potential to transform the treatment of various diseases and improve patient outcomes.

Protalix's pipeline includes several advanced-stage programs, most notably PRX-102, a potential treatment for Gaucher disease. PRX-102 has shown encouraging results in clinical trials, and its potential approval could significantly impact the company's financial position and market presence. Additionally, Protalix is exploring other therapeutic areas, such as oncology, chronic pain, and inflammatory diseases, broadening its potential market reach and enhancing its long-term growth prospects.

Beyond its promising product pipeline, Protalix possesses several strengths that position it well for future success. The company's proprietary plant cell culture platform technology offers unique advantages, including cost-effective production, scalability, and the ability to produce complex proteins that are difficult to manufacture using traditional methods. Protalix's strong intellectual property portfolio further strengthens its competitive position and provides a foundation for continued innovation.

While Protalix has a promising future, it is not without challenges. The biotech industry is highly competitive, and regulatory approvals for new drugs can be lengthy and complex. Moreover, the company may face competition from other emerging technologies and therapies. Despite these challenges, Protalix's focus on innovation, its strong pipeline, and its experienced management team position it well to overcome these hurdles and achieve long-term success.

Protalix BioTherapeutics' Robust Operating Efficiency Paves the Way for Future Growth

Protalix BioTherapeutics Inc. (DE), known for its pioneering work in protein therapeutics, has consistently demonstrated exceptional operating efficiency. The company's strategic focus on research and development (R&D), coupled with its lean operating structure and effective cost management, has enabled it to maximize its resources and deliver innovative therapies to patients.

Protalix's commitment to R&D is evident in its substantial investment in cutting-edge technologies and platforms. The company's robust pipeline of novel therapies, including its lead candidate PRX-102 for the treatment of Gaucher disease, underscores its dedication to addressing unmet medical needs. Despite significant investments in R&D, Protalix has maintained a lean operating structure, optimizing its resources and streamlining its processes. This approach has allowed the company to allocate more funds to its core activities, driving innovation and accelerating the development of its therapeutic pipeline.

Protalix's financial discipline and prudent cost management have further contributed to its operating efficiency. The company's prudent approach to expenses has enabled it to minimize administrative and overhead costs, maximizing the impact of its R&D investments. Moreover, Protalix has entered into strategic partnerships and collaborations, leveraging external expertise and resources to accelerate its development programs. These partnerships have allowed the company to share costs and risks, further enhancing its operating efficiency.

Protalix's strong operating efficiency is a key driver of its long-term success. The company's ability to optimize its resources, control costs, and maintain a lean operating structure has positioned it for continued growth and innovation. As Protalix advances its pipeline of therapies and expands its commercial operations, its focus on operating efficiency will be instrumental in driving profitability and delivering value to shareholders.

Risk Assessment of Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Inc. (DE), referred to as Protalix, is a clinical-stage biopharmaceutical company developing innovative therapies for orphan diseases and rare disorders. While the company has the potential for growth, it also faces a number of risks and challenges that must be considered.

One significant risk is Protalix's dependence on a limited number of products. Its lead product candidate, PRX-102, is still in clinical trials, and the company's other pipeline candidates are at earlier stages of development. If PRX-102 fails to achieve regulatory approval or commercial success, it could have a devastating impact on Protalix's business.

Furthermore, Protalix operates in a highly competitive industry, with several other companies developing similar therapies. Competition could intensify as other companies' products reach the market, potentially limiting Protalix's market share and profitability.

Lastly, Protalix faces financial risks. The company has a history of operating losses, and it may continue to experience negative cash flow in the future. This could make it difficult for Protalix to raise additional capital to fund its operations and clinical trials.

Overall, Protalix offers the potential for growth and innovation, but it also faces a number of challenges and risks that investors should carefully consider before making investment decisions.


  1. Candès E, Tao T. 2007. The Dantzig selector: statistical estimation when p is much larger than n. Ann. Stat. 35:2313–51
  2. S. Proper and K. Tumer. Modeling difference rewards for multiagent learning (extended abstract). In Proceedings of the Eleventh International Joint Conference on Autonomous Agents and Multiagent Systems, Valencia, Spain, June 2012
  3. Scholkopf B, Smola AJ. 2001. Learning with Kernels: Support Vector Machines, Regularization, Optimization, and Beyond. Cambridge, MA: MIT Press
  4. Kitagawa T, Tetenov A. 2015. Who should be treated? Empirical welfare maximization methods for treatment choice. Tech. Rep., Cent. Microdata Methods Pract., Inst. Fiscal Stud., London
  5. Cortes C, Vapnik V. 1995. Support-vector networks. Mach. Learn. 20:273–97
  6. Li L, Chu W, Langford J, Moon T, Wang X. 2012. An unbiased offline evaluation of contextual bandit algo- rithms with generalized linear models. In Proceedings of 4th ACM International Conference on Web Search and Data Mining, pp. 297–306. New York: ACM
  7. Z. Wang, T. Schaul, M. Hessel, H. van Hasselt, M. Lanctot, and N. de Freitas. Dueling network architectures for deep reinforcement learning. In Proceedings of the International Conference on Machine Learning (ICML), pages 1995–2003, 2016.


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.